News | May 18, 2021
Outlook promising for Cipla: HDFC Securities
The outlook for the US business remains good as respiratory pipeline (gAbraxane, gAdvair, gDulera) adds medium-term growth visibility.
The outlook for the US business remains good as respiratory pipeline (gAbraxane, gAdvair, gDulera) adds medium-term growth visibility.
The company plans to aggressively invest in longer gestation period projects like innovation, biosimilars, vaccines, etc.
The deal is to sell one of the two business undertakings of ZAHL for a lump sum consideration of Rs. 2921 crores on a cash free and debt free basis,
BBIL had proposed to carry out Phase II/III clinical trial of Covaxin in the age group of 2 to 18 years
It reported total income of Rs.15299.25 crores during the FY ended March 31, 2021
The tablets will be manufactured and marketed under Vivimed’s brand name “Favulous” across India
The drug accumulates in the virus infected cells and prevents virus growth by stopping viral synthesis and energy production
Jubilant successfully challenged Bracco's patent infringement claims in an Inter Parties Review (IPR) proceeding before the U.S. Patent Office
Seven manufacturers of Remdesivir have increased production capacity to 1.03 crore vials per month up from 38 lakh vials per month a month ago
The progress has been encouraging with approvals and launches in the US, EU, Japan, Australia and Emerging Markets. Post Mylan Upjohn (Pfizer) merger, the scope has been extended to China as well.
Subscribe To Our Newsletter & Stay Updated
